Inactive Instrument

Vitro Diagnostics, Inc.

VODG

US9285013036

Vitro Diagnostics, Inc. Reports Earnings Results for the First Quarter Ended January 31, 2021

April 28, 2021

Vitro Diagnostics Inc. announced earnings results for the first quarter ended January 31, 2021. For the first quarter, the company announced total revenue was USD 127,492 compared to USD 225,921 a year ago. Operating loss was USD 921,363 compared to USD 193,428 a year ago. Net loss was USD 1.030 million compared to USD 268,074 a year ago.

Latest news about Vitro Diagnostics, Inc.

Vitro Biopharma, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended April 30, 2024	05-31	CI
Vitro Biopharma, Inc. announced that it has received $0.3 million in funding	05-12	CI
Vitro Biopharma, Inc. announced that it has received $0.175 million in funding	04-10	CI
Vitro Biopharma, Inc. Reports Earnings Results for the First Quarter Ended January 31, 2024	03-14	CI
Vitro Biopharma, Inc. Reports Earnings Results for the Full Year Ended October 31, 2023	01-29	CI
Vitro Biopharma, Inc. Announces Chief Financial Officer Changes	01-23	CI
Vitro Biopharma, Inc. announced that it has received $1 million in funding	01-09	CI
Vitro Biopharma, Inc. announced a financing transaction	11-15	CI
Vitro Biopharma, Inc. announced that it expects to receive $2 million in funding	11-15	CI
Vitro Biopharma, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended July 31, 2023	28/08/23	CI
Vitro Biopharma, Inc. announced that it has received $0.1 million in funding	12/07/23	CI
Vitro Biopharma, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended April 30, 2023	13/06/23	CI
Vitro Biopharma, Inc. announced that it has received $0.325 million in funding	12/06/23	CI
Vitro Biopharma, Inc. announced that it has received $0.1 million in funding	04/06/23	CI
Vitro Biopharma, Inc. announced that it has received $0.2 million in funding	13/04/23	CI
Vitro Biopharma, Inc. announced that it expects to receive CAD 0.2376 million in funding	14/03/23	CI
Vitro Biopharma, Inc. Reports Earnings Results for the First Quarter Ended January 31, 2023	14/03/23	CI
Vitro Biopharma, Inc. Reports Earnings Results for the First Quarter Ended January 31, 2023	14/03/23	CI
Vitro Biopharma, Inc. Reports Earnings Results for the Full Year Ended October 31, 2022	30/01/23	CI
Vitro Biopharma, Inc. Auditor Raises 'Going Concern' Doubt	29/01/23	CI
Vitro Biopharma, Inc. amended terms of the transaction	22/01/23	CI
Vitro Biopharma, Inc. announced a financing transaction	05/01/23	CI
Vitro Biopharma, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended July 31, 2022	03/11/22	CI
Vitro Biopharma, Inc. has filed an IPO in the amount of $17.25 million.	09/09/22	CI
Vitro Biopharma Inc. Auditor Raises 'Going Concern' Doubt	08/09/22	CI

Chart Vitro Diagnostics, Inc.

Duration

Period

More charts

Company Profile

Vitro Diagnostics, Inc., doing business as Vitro Biopharma, is engaged in the development, manufacturing and distribution of stem cell products and related tools for use in research, drug discovery and clinical trials. The Company's clinical products include clinical grade MSC-Gro for mesenchymal stem cell (MSC) expansion prior to transplantation; an equine MSC cell line with application to treatment of skeletal muscular conditions, such as tendonitis, ligament injury, osteoarthritis and accelerated bone fracture healing, and others; testing and therapies related to endogenous stem cell activation; diagnostic testing of stem cell activation and determination of stem cell functional status, and cell-based assays for discovery of stem cell activation agents and new drugs for the treatment of osteoporosis. The Company offers cancer-associated fibroblasts (CAFs), which are used in the discovery of a new type of CAFs present in pancreatic cancer tumors, called pancreatic stellate cells.

Sector

Pharmaceuticals

More about the company

Sector Biopharmaceuticals

	1st Jan change	Capi.
SAMSUNG BIOLOGICS CO.,LTD.	+6.58%	41.61B
BIOGEN INC.	-11.57%	33.32B
UCB	+78.26%	28.8B
BIOMARIN PHARMACEUTICAL INC.	-14.73%	15.61B
INCYTE CORPORATION	-6.00%	13.27B
BEIJING WANTAI BIOLOGICAL PHARMACY ENTERPRISE CO., LTD.	-12.55%	11.46B
ALTEOGEN INC.	+166.50%	10.06B
CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO., LTD.	-54.80%	9.09B
SWEDISH ORPHAN BIOVITRUM AB	+3.00%	8.9B

Biopharmaceuticals